These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17001523)

  • 1. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.
    Zhang D; Pier T; McNeel DG; Wilding G; Friedl A
    Invest New Drugs; 2007 Feb; 25(1):49-55. PubMed ID: 17001523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
    McNeel DG; Eickhoff J; Lee FT; King DM; Alberti D; Thomas JP; Friedl A; Kolesar J; Marnocha R; Volkman J; Zhang J; Hammershaimb L; Zwiebel JA; Wilding G
    Clin Cancer Res; 2005 Nov; 11(21):7851-60. PubMed ID: 16278408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
    Mundhenke C; Thomas JP; Wilding G; Lee FT; Kelzc F; Chappell R; Neider R; Sebree LA; Friedl A
    Clin Cancer Res; 2001 Nov; 7(11):3366-74. PubMed ID: 11705849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
    Cai W; Chen X
    Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
    Gutheil JC; Campbell TN; Pierce PR; Watkins JD; Huse WD; Bodkin DJ; Cheresh DA
    Clin Cancer Res; 2000 Aug; 6(8):3056-61. PubMed ID: 10955784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
    Delbaldo C; Raymond E; Vera K; Hammershaimb L; Kaucic K; Lozahic S; Marty M; Faivre S
    Invest New Drugs; 2008 Feb; 26(1):35-43. PubMed ID: 17876527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
    Shin IS; Jang BS; Danthi SN; Xie J; Yu S; Le N; Maeng JS; Hwang IS; Li KC; Carrasquillo JA; Paik CH
    Bioconjug Chem; 2007; 18(3):821-8. PubMed ID: 17375899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
    O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
    Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice.
    Steri V; Ellison TS; Gontarczyk AM; Weilbaecher K; Schneider JG; Edwards D; Fruttiger M; Hodivala-Dilke KM; Robinson SD
    Circ Res; 2014 Jan; 114(1):79-91. PubMed ID: 24103390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
    Rüegg C; Dormond O; Foletti A
    Endothelium; 2002; 9(3):151-60. PubMed ID: 12380640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
    White B; Leon F; White W; Robbie G
    Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
    Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
    Abdollahi A; Griggs DW; Zieher H; Roth A; Lipson KE; Saffrich R; Gröne HJ; Hallahan DE; Reisfeld RA; Debus J; Niethammer AG; Huber PE
    Clin Cancer Res; 2005 Sep; 11(17):6270-9. PubMed ID: 16144931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
    Yap TA; Olmos D; Brunetto AT; Tunariu N; Barriuso J; Riisnaes R; Pope L; Clark J; Futreal A; Germuska M; Collins D; deSouza NM; Leach MO; Savage RE; Waghorne C; Chai F; Garmey E; Schwartz B; Kaye SB; de Bono JS
    J Clin Oncol; 2011 Apr; 29(10):1271-9. PubMed ID: 21383285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects.
    Son HN; Nam JO; Kim S; Kim IS
    Biochim Biophys Acta; 2013 Oct; 1833(10):2378-88. PubMed ID: 23792174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.